Association between high-threshold practices and buprenorphine treatment termination

Valencia Lyle,Samantha Harris,Omeid Heidari,Kathryn Boulton,Eric Hulsey,Brendan Saloner,Jason Gibbons

DOI: https://doi.org/10.1016/j.drugpo.2024.104318

IF: 5.931

2024-01-19

International Journal of Drug Policy

Abstract:Background Regular counseling and frequent drug testing are common requirements for patients with opioid use disorder in buprenorphine treatment. State policies throughout the United States often reinforce these high-threshold practices, as was the case with Michigan, USA. Methods We sought to explore the association between counseling requirements, drug testing practices, and buprenorphine treatment termination rates through administering a survey to buprenorphine prescribers in Michigan. Results In our sample of 377 prescribers, we found associations between high-threshold practices like drug testing at every clinical visit and requiring counseling and buprenorphine treatment termination rates. Relative to prescribers who randomly drug tested, drug tested at fixed intervals, or did not require any drug testing, prescribers who drug-tested patients at every visit were 38% more likely to terminate treatment. Prescribers who required counseling were 33% more likely to terminate treatment than those who did not require counseling. Conclusion With the elimination of the USA Drug Enforcement Administration X-waiver in December 2022, state policies need to minimize high-threshold practices that reduce buprenorphine treatment continuity and undermine an effective response to the overdose crisis.

substance abuse